2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
This guideline cites 26 of the 199 landmark trials in our Cardiology register.
- Issued by
- ACC/
AHA - Year
- 2022
- Source
- Heidenreich PA, Bozkurt B, et al. Circulation. 2022;145(18):e895–e1032.doi 10.1161/CIR.0000000000001063
The US guideline shares the four foundational HFrEF drug classes with the ESC but frames them differently: it adopts the universal definition with stages A–D ('at risk', 'pre-HF'), introduces HF with improved ejection fraction (HFimpEF), and — unusually for a guideline — attaches explicit cost-effectiveness value statements to each therapy. Two substantive differences from the ESC 2021 text: SGLT2 inhibitors are recommended across HFmrEF and HFpEF (Class 2a, on EMPEROR-Preserved), which the ESC only caught up with in its 2023 Focused Update; and the primary-prevention ICD keeps a Class 1 recommendation irrespective of aetiology, whereas the ESC downgraded non-ischaemic dilated cardiomyopathy to Class IIa after DANISH. The register's heart-failure trials are grouped below.
Foundational HFrEF therapy (four pillars)12
- 2020EMPEROR-ReducedCardiology · HF · SGLT2 inhibitorsIn 3,730 patients with HFrEF (EF ≤ 40 %), empagliflozin reduced cardiovascular death or heart-failure hospitalisation compared with placebo.HR 0.75Read →
- 2019DAPA-HF CoreCardiology · HF · SGLT2 inhibitorsIn 4,744 patients with HFrEF (with or without diabetes), dapagliflozin reduced worsening HF or CV death versus placebo.HR 0.74Read →
- 2019PIONEER-HFCardiology · HF · ARNIIn 881 patients hospitalised for acute decompensated HFrEF, in-hospital initiation of sacubitril/valsartan lowered NT-proBNP more than enalapril.-46.7% vs -25.3%Read →
- 2014PARADIGM-HF CoreCardiology · HF · ARNIIn 8,442 patients with HFrEF (EF ≤ 0.40), sacubitril/valsartan reduced CV death or hospitalisation for HF compared with enalapril.HR 0.8Read →
- 2011EMPHASIS-HFCardiology · HF · MRAIn 2,737 patients with mild HFrEF (NYHA II, EF ≤ 35 %), eplerenone reduced cardiovascular death or heart-failure hospitalisation compared with placebo.HR 0.63Read →
- 2004A-HeFTCardiology · HF · hydralazine/nitrateIn 1,050 Black patients with NYHA III-IV HFrEF on standard therapy, fixed-dose isosorbide dinitrate plus hydralazine improved a composite of survival, HF hospitalisation and quality of life compared with placebo.HR 0.57Read →
- 2003CHARMCardiology · HF · ARBIn 7,601 patients with symptomatic chronic heart failure, candesartan reduced cardiovascular death and heart-failure hospitalisation compared with placebo.HR 0.9195% CI 0.83-1.00Read →
- 2001COPERNICUSCardiology · HF · beta-blockerIn 2,289 patients with severe heart failure and EF ≤ 25%, carvedilol reduced all-cause mortality compared with placebo.11.2% vs 16.8%Read →
- 1999RALES CoreCardiology · HF · MRAIn 1,663 patients with severe HFrEF on ACEi, spironolactone 25 mg reduced all-cause mortality compared with placebo.RR 0.7095% CI 0.60-0.82Read →
- 1999MERIT-HF CoreCardiology · HF · Beta-blockadeIn 3,991 patients with HFrEF (EF ≤ 0.40, NYHA II–IV), metoprolol CR/XL reduced all-cause mortality compared with placebo.Read →
- 1991SOLVDCardiology · HF · ACE inhibitorIn 2,569 patients with symptomatic heart failure and EF ≤ 0.35, enalapril reduced all-cause mortality compared with placebo.35.2% vs 39.7%Read →
- 1987CONSENSUS CoreCardiology · HF · RAAS inhibitionIn 253 patients with NYHA IV heart failure, enalapril reduced 6-month mortality versus placebo.26% vs 44%Read →
HFmrEF & HFpEF2
- 2021EMPEROR-Preserved CoreCardiology · HF · SGLT2 inhibitorsIn 5,988 patients with HFpEF (EF > 40 %), empagliflozin reduced HF hospitalisation or CV death compared with placebo.HR 0.7995% CI 0.69-0.90Read →
- 2014TOPCATCardiology · HF · MRAIn 3,445 patients with HFpEF (EF ≥ 45%), spironolactone did not significantly reduce cardiovascular death, aborted cardiac arrest, or heart-failure hospitalisation compared with placebo.HR 0.8995% CI 0.77-1.04Read →
Adjunctive therapy, exercise & advanced HF4
- 2020VICTORIACardiology · HF · sGC stimulatorIn 5,050 patients with worsening HFrEF (EF < 45%), vericiguat reduced cardiovascular death or first heart-failure hospitalisation compared with placebo.HR 0.9095% CI 0.82-0.98Read →
- 2016STICHCardiology · HF · CABGIn 1,212 patients with ischaemic cardiomyopathy (EF ≤ 35%) and CAD, coronary-artery bypass grafting plus medical therapy reduced 10-year all-cause mortality compared with medical therapy alone.HR 0.8495% CI 0.73-0.97Read →
- 2010SHIFTCardiology · HF · If-channel inhibitorIn 6,558 patients with HFrEF (EF ≤ 35%) in sinus rhythm with heart rate ≥ 70 bpm, ivabradine reduced cardiovascular death or hospitalisation for worsening heart failure compared with placebo.HR 0.8295% CI 0.75-0.90Read →
- 2009HF-ACTIONCardiology · HF · Exercise trainingIn 2,331 patients with heart failure and reduced ejection fraction, a supervised aerobic exercise-training programme did not significantly reduce all-cause mortality or hospitalisation compared with usual care.HR 0.9395% CI 0.84-1.02Read →
Cardiac amyloidosis (ATTR)1
- 2018ATTR-ACT CoreCardiology · HF · CardiomyopathyIn 441 patients with transthyretin amyloid cardiomyopathy, tafamidis reduced all-cause mortality and cardiovascular hospitalisation compared with placebo.HR 0.7Read →
Device therapy: ICD & CRT7
- 2016DANISHCardiology · Arrhythmia · ICDIn 1,116 patients with non-ischaemic heart failure (EF ≤ 35 %), a prophylactic defibrillator did not reduce all-cause mortality compared with usual care.HR 0.87Read →
- 2010RAFTCardiology · Arrhythmia · CRTIn 1,798 patients with NYHA II-III heart failure, EF ≤ 30% and wide QRS, adding cardiac resynchronisation to an ICD reduced death or heart-failure hospitalisation compared with an ICD alone.HR 0.7595% CI 0.64-0.87Read →
- 2009MADIT-CRTCardiology · Arrhythmia · CRTIn 1,820 patients with mild heart failure (NYHA I–II) and a wide QRS, adding resynchronisation to a defibrillator reduced death or heart-failure events compared with a defibrillator alone.HR 0.66Read →
- 2005SCD-HeFT CoreCardiology · Arrhythmia · ICDIn 2,521 patients with heart failure (NYHA II–III, EF ≤ 35 %), an implantable defibrillator reduced all-cause mortality compared with placebo or amiodarone.Read →
- 2005CARE-HF CoreCardiology · Arrhythmia · CRTIn 813 patients with heart failure and a wide QRS, cardiac resynchronisation therapy reduced death or unplanned cardiovascular hospitalisation compared with medical therapy.39% vs 55%Read →
- 2004COMPANIONCardiology · Arrhythmia · CRTIn 1,520 patients with NYHA III-IV heart failure and QRS ≥ 120 ms, cardiac resynchronisation therapy (with or without a defibrillator) reduced all-cause death or hospitalisation compared with optimal medical therapy alone.Read →
- 2002MADIT-II CoreCardiology · Arrhythmia · ICDIn 1,232 patients with prior MI and an ejection fraction ≤ 30 %, a prophylactic implantable defibrillator reduced all-cause mortality compared with conventional therapy.HR 0.69Read →
Published since the guideline6
- 2025SUMMITCardiology · Cardiometabolic · Obesity & HFpEFIn 731 patients with HFpEF and obesity, tirzepatide reduced cardiovascular death or worsening heart failure compared with placebo.HR 0.62Read →
- 2024FINEARTS-HFCardiology · HF · MRAIn 6,001 patients with heart failure and an ejection fraction ≥ 40 %, finerenone reduced worsening-heart-failure events and cardiovascular death compared with placebo.IRR 0.84Read →
- 2024ATTRibute-CMCardiology · HF · TTR stabiliserIn 632 patients with transthyretin amyloid cardiomyopathy, acoramidis improved a hierarchical composite of death, CV hospitalisation, NT-proBNP and 6-minute walk distance compared with placebo.WR 1.895% CI 1.4-2.2Read →
- 2023STEP-HFpEFCardiology · HF · GLP-1 RAIn 529 patients with HFpEF (EF ≥ 45%) and obesity (BMI ≥ 30) without diabetes, semaglutide 2.4 mg improved heart-failure symptoms (KCCQ) and body weight compared with placebo.Read →
- 2022DELIVERCardiology · HF · SGLT2 inhibitorsIn 6,263 patients with heart failure and an ejection fraction > 40 %, dapagliflozin reduced worsening heart failure or cardiovascular death compared with placebo.HR 0.82Read →
- 2022STRONG-HFCardiology · HF · GDMT up-titrationIn 1,078 patients recently hospitalised for acute heart failure, rapid up-titration of guideline-directed therapy with close follow-up reduced 180-day death or heart-failure readmission compared with usual care.RR 0.6695% CI 0.50-0.86Read →
Cited landmark trials not yet in the register5
Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.
- 2020AFFIRM-AHF
IV ferric carboxymaltose in acute HF with iron deficiency.
- 2021GALACTIC-HF
Omecamtiv mecarbil (cardiac myosin activator) in HFrEF.
- 2019MOMENTUM 3
Fully magnetically levitated LVAD in advanced heart failure.
- 2011CHAMPION
Implantable pulmonary-artery pressure monitoring (CardioMEMS).
- 1997DIG
Digoxin reduced hospitalisation but not mortality.
Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.